Diffuse Large B-Cell Lymphoma-Recurrent
10 clinical trials · Condition
◉ Watch Diffuse Large B-Cell Lymphoma-Recurrent
| Record | Firm | Date |
|---|---|---|
| Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL (NCT03795571) | The First Affiliated Hospital with Nanjing Medical University | 2019-01-01 |
| Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT03589469) | ADC Therapeutics S.A. | 2018-08-01 |
| RICE-ibrutinib in Relapsed DLBCL (NCT02955628) | Singapore General Hospital | 2016-12-13 |
| The Use of Biomarkers to Predict CNS Involvement in Diffuse Large B-Cell Lymphoma: a Danish Nationwide Registry Study (NCT05169203) | Herlev Hospital | 2014-01-01 |
| Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. (NCT01805557) | Fondazione Italiana Linfomi - ETS | 2013-02-04 |
Track Diffuse Large B-Cell Lymphoma-Recurrent automatically
Every clearance here is in the API, with alerts when new ones post.